Special Issue "Treatment of Dystonia with Botulinum Toxins"

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".

Deadline for manuscript submissions: closed (28 February 2020).

Special Issue Editors

Prof. David Charles
Website
Guest Editor
Vanderbilt University Medical Center, 1161 21st Avenue South, Suite A-1106 MCN, Nashville, TN 37232, USA
Prof. Peter Hedera
Website
Guest Editor
Vanderbilt University Medical Center, 1161 21st Avenue South, Suite A-1106 MCN, Nashville, TN 37232, USA

Special Issue Information

Dear Colleagues,

The treatment of focal dystonia has been revolutionized by botulinum toxins. First approved in 1989 by the US Food and Drug Administration, botulinum toxin injection is now the worldwide mainstay therapy for this often painful and disabling condition. There are several safe and effective botulinum toxins, and more are under development.

This Special Issue of Toxins focuses on treatment of the different focal dystonias and provides an overview of available botulinum products and relevant practice guidelines. Included in this Special Issue are in-depth discussions of the treatment of cervical dystonia, blepharospasm, oromandibular dystonia, task specific dystonia, and other limb dystonias.

Prof. David Charles
Prof. Peter Hedera
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dystonia
  • cervical dystonia
  • blepharospasm
  • oromandibular dystonia
  • botulinum toxin
  • onobotulinumtoxinA
  • abobotulinumtoxinA
  • incabotulinumtoxinA
  • rimabotulinumtoxinB
  • daxibotulinumtoxinA

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia
Toxins 2020, 12(5), 332; https://doi.org/10.3390/toxins12050332 - 17 May 2020
Abstract
In 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies that led to [...] Read more.
In 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies that led to Food and Drug Administration (FDA) approval of each toxin for dystonia indications are reviewed, in addition to several studies highlighted by the AAN guidelines. The AAN guidelines for the use of BoNT in dystonia are compared with those of the European Federation of the Neurological Societies (EFNS), and common off-label uses for BoNT in dystonia are discussed. Toxins not currently FDA-approved for the treatment of dystonia are additionally reviewed. In the future, additional toxins may become FDA-approved for the treatment of dystonia given expanding research in this area. Full article
(This article belongs to the Special Issue Treatment of Dystonia with Botulinum Toxins)
Open AccessReview
Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins
Toxins 2020, 12(4), 269; https://doi.org/10.3390/toxins12040269 - 22 Apr 2020
Abstract
Blepharospasm and oromandibular dystonia are focal dystonias characterized by involuntary and often patterned, repetitive muscle contractions. There is a long history of medical and surgical therapies, with the current first-line therapy, botulinum neurotoxin (BoNT), becoming standard of care in 1989. This comprehensive review [...] Read more.
Blepharospasm and oromandibular dystonia are focal dystonias characterized by involuntary and often patterned, repetitive muscle contractions. There is a long history of medical and surgical therapies, with the current first-line therapy, botulinum neurotoxin (BoNT), becoming standard of care in 1989. This comprehensive review utilized MEDLINE and PubMed and provides an overview of the history of these focal dystonias, BoNT, and the use of toxin to treat them. We present the levels of clinical evidence for each toxin for both, focal dystonias and offer guidance for muscle and site selection as well as dosing. Full article
(This article belongs to the Special Issue Treatment of Dystonia with Botulinum Toxins)
Show Figures

Figure 1

Back to TopTop